BIM 23A761, selective for somatostatin receptors subtypes 2, 5 and the dopamine receptor subtype 2, and BIM 23A757 with affinity for SSTR2 and DAR2 were studied on human PBL proliferation and activation. BIM 23A761 was significantly more potent than specific SSTR and DAR2 agonists in suppressing lymphocyte proliferation induced by mitogen or alloantigen, while BIM 23A757 was more potent than specific SSTR2 and DAR2 agonists in suppressing antigen induced proliferation only. Both molecules displayed enhanced potency in suppressing IFNgamma and IL-6 secretion compared with the SSTR and DAR2 analogs, while only BIM 23A761 was able to inhibit IL-2 secretion and its effect is more potent than the control analogs. Furthermore BIM 23A761 inhibit cell progression into the S phase and then into the G2/M, while BIM 23A757 inhibited bromodeoxyuridine incorporation only during the S phase. Both chimeric molecules resulted significantly more effective than the respective controls.

Effects of chimeric somatostatin-dopamine molecules on human peripheral blood lymphocytes activation / C. Casnici, D.F. Lattuada, K. Crotta, C. Mastrotto, P. Franco, M.D. Culler, O. Marelli. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 179:1-2(2006 Oct), pp. 9-17.

Effects of chimeric somatostatin-dopamine molecules on human peripheral blood lymphocytes activation

C. Casnici
Primo
;
D.F. Lattuada
Secondo
;
K. Crotta;P. Franco;O. Marelli
Ultimo
2006

Abstract

BIM 23A761, selective for somatostatin receptors subtypes 2, 5 and the dopamine receptor subtype 2, and BIM 23A757 with affinity for SSTR2 and DAR2 were studied on human PBL proliferation and activation. BIM 23A761 was significantly more potent than specific SSTR and DAR2 agonists in suppressing lymphocyte proliferation induced by mitogen or alloantigen, while BIM 23A757 was more potent than specific SSTR2 and DAR2 agonists in suppressing antigen induced proliferation only. Both molecules displayed enhanced potency in suppressing IFNgamma and IL-6 secretion compared with the SSTR and DAR2 analogs, while only BIM 23A761 was able to inhibit IL-2 secretion and its effect is more potent than the control analogs. Furthermore BIM 23A761 inhibit cell progression into the S phase and then into the G2/M, while BIM 23A757 inhibited bromodeoxyuridine incorporation only during the S phase. Both chimeric molecules resulted significantly more effective than the respective controls.
receptors dimerization; somatostatin receptors; dopamine receptors; human lymphocytes
Settore BIO/14 - Farmacologia
ott-2006
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S016557280600258X-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 623.9 kB
Formato Adobe PDF
623.9 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/24643
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact